|
1
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saraf AJ, Fenger JM and Roberts RD:
Osteosarcoma: Accelerating progress makes for a hopeful future.
Front Oncol. 8:42018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu J, Wang H, Hu Y, Zhang YS, Wen L, Yin
F, Wang Z, Zhang Y, Li S, Miao Y, et al: Inhibition of CaMKIIα
activity enhances antitumor effect of fullerene C60 nanocrystals by
suppression of autophagic degradation. Adv Sci (Weinh). 6:1801233.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu JL, Li J, Xu JJ, Xiao F, Cui PL, Qiao
ZG, Chen XD, Tao WD and Zhang XL: miR-144 inhibits tumor growth and
metastasis in osteosarcoma via dual-suppressing RhoA/ROCK1
signaling pathway. Mol Pharmacol. 95:451–461. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jianwei Z, Fan L, Xiancheng L, Enzhong B,
Shuai L and Can L: MicroRNA 181a improves proliferation and
invasion, suppresses apoptosis of osteosarcoma cell. Tumour Biol.
34:3331–3337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen Z, Zhao G, Zhang Y, Ma Y, Ding Y and
Xu N: miR-199b-5p promotes malignant progression of osteosarcoma by
regulating HER2. J BUON. 23:1816–1824. 2018.PubMed/NCBI
|
|
10
|
Zhu KP, Zhang CL, Ma XL, Hu JP, Cai T and
Zhang L: Analyzing the interactions of mRNAs and ncRNAs to predict
competing endogenous RNA networks in osteosarcoma chemo-resistance.
Mol Ther. 27:518–530. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun L, Liu M, Luan S, Shi Y and Wang Q:
MicroRNA-744 promotes carcinogenesis in osteosarcoma through
targeting LATS2. Oncol Lett. 18:2523–2529. 2019.PubMed/NCBI
|
|
12
|
Li JZ, Gao W, Lei WB, Zhao J, Chan JY, Wei
WI, Ho WK and Wong TS: MicroRNA 744-3p promotes MMP-9-mediated
metastasis by simultaneously suppressing PDCD4 and PTEN in
laryngeal squamous cell carcinoma. Oncotarget. 7:58218–58233.
2016.PubMed/NCBI
|
|
13
|
Tamura M, Gu J, Matsumoto K, Aota S,
Parsons R and Yamada KM: Inhibition of cell migration, spreading,
and focal adhesions by tumor suppressor PTEN. Science.
280:1614–1617. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosenberg AE, Cleton-Jansen AM, de Pineux
G, Deyrup AT, Hauben E and Squire J: Conventional osteosarcoma. WHO
Classification of Tumours of Soft Tissue and Bone. 4th. Fletcher
CDM, Bridge JA, Hogendoorn CWH and Mertens F: IARC Press; Lyon: pp.
282–288. 2013
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sansal I and Sellers WR: The biology and
clinical relevance of the PTEN tumor suppressor pathway. J Clin
Oncol. 22:2954–2963. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang H, Kong W, He L, Zhao JJ, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ:
MicroRNA expression profiling in human ovarian cancer: miR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Wang F, Li M, Yu Z, Qi R, Ding J,
Zhang Z and Chen X: Self-Stabilized hyaluronate nanogel for
intracellular codelivery of doxorubicin and cisplatin to
osteosarcoma. Adv Sci (Weinh). 5:17008212018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li S, Zhang T, Xu W, Ding J, Yin F, Xu J,
Sun W, Wang H, Sun M, Cai Z and Hua Y: Sarcoma-targeting
peptide-decorated polypeptide nanogel intracellularly delivers
shikonin for upregulated osteosarcoma necroptosis and diminished
pulmonary metastasis. Theranostics. 8:1361–1375. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou W, Li Y, Gou S, Xiong J, Wu H, Wang
C, Yan H and Liu T: miR-744 increases tumorigenicity of pancreatic
cancer by activating Wnt/β-catenin pathway. Oncotarget.
6:37557–37569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang M and Li H, Zhang Y and Li H:
Oncogenic miR-744 promotes prostate cancer growth through direct
targeting of LKB1. Oncol Lett. 17:2257–2265. 2019.PubMed/NCBI
|
|
23
|
Yu Q, Zhang F, Du Z and Xiang Y:
Up-regulation of serum miR-744 predicts poor prognosis in patients
with nasopharyngeal carcinoma. Int J Clin Exp Med. 8:13296–13302.
2015.PubMed/NCBI
|
|
24
|
Deng Y, Li Y, Fang Q, Luo H and Zhu G:
microRNA-744 is downregulated in glioblastoma and inhibits the
aggressive behaviors by directly targeting NOB1. Am J Cancer Res.
8:2238–2253. 2018.PubMed/NCBI
|
|
25
|
Xu AJ, Fu LN, Wu HX, Yao XL and Meng R:
MicroRNA744 inhibits tumor cell proliferation and invasion of
gastric cancer via targeting brainderived neurotrophic factor. Mol
Med Rep. 16:5055–5061. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen J and Li M: MicroRNA-744 inhibits
cellular proliferation and invasion of colorectal cancer by
directly targeting oncogene Notch1. Oncol Res. Feb 22–2018.(Epub
ahead of print). View Article : Google Scholar
|
|
27
|
Tan YL, Bai ZG, Zou WL, Ma XM, Wang TT,
Guo W, Liu J, Li JS, Jie-Yin, Zang YJ and Zhang ZT: miR-744 is a
potential prognostic marker in patients with hepatocellular
carcinoma. Clin Res Hepatol Gastroenterol. 39:359–365. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Colakoglu T, Yildirim S, Kayaselcuk F,
Nursal TZ, Ezer A, Noyan T, Karakayali H and Haberal M:
Clinicopathological significance of PTEN loss and the
phosphoinositide 3-kinase/Akt pathway in sporadic colorectal
neoplasms: Is PTEN loss predictor of local recurrence? Am J Surg.
195:719–725. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saal LH, Holm K, Maurer M, Memeo L, Su T,
Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, et al:
PIK3CA mutations correlate with hormone receptors, node metastasis,
and ERBB2, and are mutually exclusive with PTEN loss in human
breast carcinoma. Cancer Res. 65:2554–2559. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang JM, He QY, Guo RX and Chang XJ:
Phosphorylated Akt overexpression and loss of PTEN expression in
non-small cell lung cancer confers poor prognosis. Lung Cancer.
51:181–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
